Memorial Sloan Kettering Cancer Center: Leukemia trials

The registry lists 84 Leukemia studies with Memorial Sloan Kettering Cancer Center as lead sponsor. 4 are open to participants now and 25 have results posted.

Phase 1 27Phase 2 51Phase 3 4Phase 4 1No phase 11(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Cord Blood Transplantation in Children and Young Adults With Blood CancerRecruitingNCT07566377Phase 2
• A Study of Revumenib and Mezigdomide in People With LeukemiaRecruitingNCT07356154Phase 1/2
• A Music Therapy Study for Blood Cancer Survivors With Cognitive DifficultiesRecruitingNCT07052916Not applicable
• Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative DisordersRecruitingNCT00582621
• Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched DonorsTerminatedNCT03615105Phase 2Results posted
• Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood TransplantationCompletedNCT03434730Phase 2Results posted
• Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant RelapseCompletedNCT01995578Phase 2Results posted
• Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible DonorTerminatedNCT01598025Not applicableResults posted
• Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission TherapyCompletedNCT01404949Phase 2Results posted
• Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic SyndromeCompletedNCT01200355Phase 4Results posted
• HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic MalignanciesCompletedNCT01119066Phase 2Results posted
• Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of AgeCompletedNCT01011894Phase 2Results posted
• Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.CompletedNCT00739141Phase 2Results posted
• Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)CompletedNCT00629798Phase 2Results posted
• Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated DonorCompletedNCT00582933Phase 2Results posted
• Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell CancerCompletedNCT00546377Phase 1/2Results posted
• Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic LeukemiaCompletedNCT00541034Phase 2Results posted
• Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic LeukemiaTerminatedNCT00528450Phase 2Results posted
• Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell TransplantCompletedNCT00526292Phase 2Results posted
• Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT00425802Phase 2Results posted
• Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other DiseaseCompletedNCT00423514Phase 1/2Results posted
• Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous TreatmentCompletedNCT00416351Phase 1/2Results posted
• Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or MesotheliomaCompletedNCT00398138Phase 1Results posted
• Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's LymphomaCompletedNCT00387959Phase 2Results posted
• Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's LymphomaCompletedNCT00295932Phase 1/2Results posted
• Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic CancerCompletedNCT00027560Phase 2Results posted
• Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid CancerCompletedNCT00014495Phase 1/2Results posted
• Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients Who Have Chronic Lymphocytic LeukemiaCompletedNCT00003659Phase 2Results posted
• Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or LymphomaCompletedNCT00002766Phase 3Results posted
• A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaWithdrawnNCT04694560
• A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk TranslocationsCompletedNCT03793140Phase 2
• Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)WithdrawnNCT03699384Phase 1/2
• A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell LeukemiaActive, not recruitingNCT03410875Phase 2
• Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to TreatmentActive, not recruitingNCT02932280Phase 1/2
• Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or OlderWithdrawnNCT02647190Phase 1
• Feasibility and Safety of Functional Performance Testing in Patients Undergoing Hematopoietic Cell TransplantationCompletedNCT02598752
• Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA GenotypesActive, not recruitingNCT02450708Not applicable
• A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic LeukemiaActive, not recruitingNCT01920737Phase 2
• Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell TransplantationActive, not recruitingNCT01746849Phase 2
• Non-Invasive Cerenkov Luminescence Imaging of Lymphoma, Leukemia and Metastatic Lymph NodesCompletedNCT01664936
• Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and RituximabCompletedNCT01416974Phase 1
• Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19Active, not recruitingNCT01044069Phase 1
• Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic LeukemiaCompletedNCT00940524Phase 1
• Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell TransplantationCompletedNCT00620633Phase 1
• Structural Imaging and Cognitive Functions in Adult Stem Cell Transplant Recipients Treated With Chemotherapy Alone or in Combination With RadiotherapyCompletedNCT00606216
• Effect of Imatinib on Bone Metabolism in Patients With Chronic Myelogenous Leukemia or Gastrointestinal Stromal TumorsCompletedNCT00580281Not applicable
• Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial CancersActive, not recruitingNCT00579163
• Abdominal Obesity and Cardiovascular Risk Factors in Women Who Survived Cancer or a Related Illness Following Total Body Irradiation and Stem Cell TransplantCompletedNCT00510315
• Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19Active, not recruitingNCT00466531Phase 1/2
• Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute LeukemiaCompletedNCT00462787Phase 1
• Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell TransplantationTerminatedNCT00087009Phase 1
• Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaCompletedNCT00081133Phase 1/2
• Monoclonal Antibody in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00058396Phase 1
• Ixabepilone in Treating Patients With Relapsed or Refractory Lymphoproliferative DisordersCompletedNCT00052572Phase 2
• Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00045422Phase 2
• Pyroxamide in Treating Patients With Advanced CancerCompletedNCT00042900Phase 1
• FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's LymphomaCompletedNCT00042822Phase 2
• Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic CancerCompletedNCT00028730Phase 2
• Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic LeukemiaCompletedNCT00016159Phase 2
• Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic CancerCompletedNCT00014469Phase 2
• PS-341 in Treating Patients With Hematologic CancerCompletedNCT00006098Phase 1
• Radiolabeled Monoclonal Antibody Therapy and Etoposide Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Myelodysplastic Syndrome or Refractory LeukemiaCompletedNCT00006040Phase 1
• Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate CancerCompletedNCT00006019Phase 2
• St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for CancerCompletedNCT00005805Phase 3
• Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous TherapyCompletedNCT00005634Phase 1
• Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic Myelogenous LeukemiaCompletedNCT00005618Phase 2
• Sodium Salicylate in Treating Patients With Advanced Myelodysplastic Syndrome, Acute Myelogenous Leukemia, or Chronic Lymphocytic LeukemiaCompletedNCT00004245Phase 1
• Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT00004215Phase 2
• Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic CancerCompletedNCT00004065Phase 1
• Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic CancerCompletedNCT00004061Phase 2
• Vaccine Therapy in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00004052Phase 2
• Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Other B-cell CancersCompletedNCT00003658Phase 2
• Arsenic Trioxide in Treating Patients With Advanced Hematologic CancerCompletedNCT00003395Phase 1
• Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By ChemotherapyCompletedNCT00003341Phase 3
• Monoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous LeukemiaCompletedNCT00002890Phase 1
• Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic SyndromeCompletedNCT00002800Phase 2
• Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia, Osteosarcoma, or Non-Hodgkin's LymphomaCompletedNCT00002738Phase 2
• T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic AnemiaCompletedNCT00002718Phase 2
• Monoclonal Antibody Therapy and Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia in RemissionCompletedNCT00002609Phase 2
• Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00002598Phase 2
• High-Dose Chemotherapy and Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Acute Leukemia in RemissionCompletedNCT00002567Phase 2
• Bone Marrow Transplantation in Treating Patients With Acute Leukemia in First or Second RemissionCompletedNCT00002534Phase 3
• Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic SyndromeCompletedNCT00002502Phase 2
• Combination Chemotherapy in Treating Patients With Acute B-Lymphoblastic Leukemia or Non-Hodgkin's LymphomaCompletedNCT00002471Phase 2